Drug Trial Radar · NCT06226090
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
314
Actual
Start
Feb 21, 2024
Primary completion
Sep 26, 2024
Study completion Oct 24, 2024
Sponsor
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic patients with overweight in the presence of comorbidities or obesity, in addition to lifestyle intervention.
Conditions
- Obesity
- Overweight
Interventions
TG103 7.5 mgDrug
Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
Placebo 7.5 mgDrug
Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
TG103 15 mgDrug
Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
Placebo 15 mgDrug
Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
TG103 22.5 mgDrug
Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
Placebo 22.5 mgDrug
Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage relative change from baseline in body weight at week 24Time frame: From baseline to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials Information Group
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.